Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Merck Serono commences ORACLE MS trial to evaluate Cladribine in MS

Sep. 18, 2008

Recent patents report novel analgesic agents

Sep. 18, 2008

Neuropharma changes name to Noscira, announces completion of phase I trials of NP-12

Sep. 18, 2008

GSK and XenoPort submit NDA to FDA for Solzira in restless legs syndrome

Sep. 18, 2008

AstraZeneca and Targacept report results from phase IIb AZD-3480 trial

Sep. 17, 2008

FDA approves Gamunex for inflammatory demyelinating polyneuropathy

Sep. 17, 2008

Final patient completes first phase III sodium oxybate trial in fibromyalgia

Sep. 17, 2008

XenoPort to initiate a phase II clinical trial of XP1-9986 in acute back spasms

Sep. 17, 2008

Keppra XR extended-release tablet approved in the U.S.

Sep. 16, 2008

Novel anxiolytic agents disclosed in recent Bial-Portela patent

Sep. 16, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...